2-Methyl-4,5-dimethoxypyrimidin | 7314-66-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methyl-4,5-dimethoxypyrimidin
• 英文别名: 4,5-Dimethoxy-2-methyl-pyrimidin；Pyrimidine, 4,5-dimethoxy-2-methyl-；4,5-dimethoxy-2-methylpyrimidine
• CAS: 7314-66-1
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: UXGVFEKDMFGWRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• HSP90 INHIBITORS
  申请人：Chen Young K.

  公开号：US20090305998A1

  公开（公告）日：2009-12-10

  The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及抑制HSP90的化合物，其由下式表示：其中变量如定义所述。本发明还涉及包括此类化合物的制药组合物、工具箱和制造物品；用于制备该化合物的方法和中间体；以及使用该化合物的方法。
• BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：Conn P. Jeffrey

  公开号：US20120225844A1

  公开（公告）日：2012-09-06

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及双环三唑和吡唑内酰胺、其衍生物和相关化合物，可作为代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• OREXIN RECEPTOR ANTAGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20150126498A1

  公开（公告）日：2015-05-07

  The disclosures herein relate to novel compounds of formula wherein W, X and Y 1 , Y 2 , Y 3 and Y 4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

  本文披露了一种公式化合物，其中W、X和Y1、Y2、Y3和Y4在此定义，并且它们在治疗、预防、改善、控制或降低与促进素受体相关的神经或精神障碍的风险方面的使用。
• Orexin receptor antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US10316028B2

  公开（公告）日：2019-06-11

  The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

  本文公开的内容涉及式中 W、X 和 Y1、Y2、Y3 和 Y4 在本文中定义的新型化合物，以及它们在治疗、预防、改善、控制或降低与奥曲肽受体相关的神经或精神疾病风险中的用途。
• US8071766B2
  申请人：——

  公开号：US8071766B2

  公开（公告）日：2011-12-06